breast cancer

Research in Review

Neoadjuvant Endocrine Therapy for Breast Cancer Produces Same Results as Combination Chemotherapy

07/08/2016

JCP Editors

Neoadjuvant endocrine therapy (NET) may be associated with similar response rates as neoadjuvant combination chemotherapy, but with significantly lower toxicity, findings from a study published in JAMA Oncology...

...

07/08/2016

Journal of Clinical Pathways

Research in Review

Genetic Testing for DCIS Unnecessary, Costing the US Millions

07/05/2016

JCP Editors

Automatically testing all core needle biopsy specimens showing ductal carcinoma in situ (DCIS) for estrogen receptor (ER) and progesterone receptor (PR) is highly expensive and may not be needed, according to a study...

...

07/05/2016

Journal of Clinical Pathways

Research in Review

Breast Cancer Treatment May Lead to Functional Decline or Death in Elderly Patients

07/01/2016

JCP Editors

Many older women diagnosed with nonmetastatic breast cancer may experience functional decline or death within 12 months of breast cancer treatment initiation, but the Vulnerable Elders Survey (VES-12) may help to...

Many...

07/01/2016

Journal of Clinical Pathways

Research in Review

Shortened Radiotherapy for Breast Cancer Supported in Study

06/22/2016

JCP Editors

A shortened course of radiotherapy for patients with early stage breast cancer may actually produce slightly better outcomes than the conventional protocol, according to the results of a randomized clinical...

A...

06/22/2016

Journal of Clinical Pathways

Clinical Insights

Cryoablation of Benign and Malignant Breast Tumors

06/21/2016

Geetika Klevos , MD;

Fernando Collado-Mesa , MD;

Jose M. Net , MD;

Monica M. Yepes , MD;

Abstract: Cryoablation is a well established, FDA approved, minimally invasive treatment modality for fibroadenomas. Additionally, several pilot studies have shown its success in the treatment of small breast cancers. It is an outpatient...

Abstract: Cryoablation is a well...

06/21/2016

IO Learning

Research in Review

Breast Cancer Biomarker of Chemotherapy Resistance Identified

05/26/2016

JCP Editors

Expression of methylation-controlled J protein (MCJ) may be an indicator of successful outcomes and reduced risk of relapse in patients with breast cancer, according to a recent study. Chemotherapy is a key part of...

...

05/26/2016

Journal of Clinical Pathways

Research in Review

Costs of Adverse Events Quantified for Breast Cancer Patients

05/24/2016

JCP Editors

Adverse events (AEs) may be a driver of high health care costs in patients with metastatic breast cancer treated with systemic therapy, according to a new study. AEs are a serious concern for patients and providers,...

...

05/24/2016

Journal of Clinical Pathways

News

Concure Oncology Launches One-Time, One-Day Radiation Treatment for Early-Stage Breast Cancer

05/12/2016

Breast Microseed Treatment Enables Women to Get Back to Living Their Lives the Very Next DaySEATTLE, May 12, 2016 /PRNewswire-USNewswire/ -- Concure Oncology/Breast Microseed, Inc., a company specializing in early-stage breast cancer...

Breast Microseed Treatment...

05/12/2016

IO Learning

Research in Review

FACT-B Most Effective Health-Related Quality of Life Instrument for Breast Cancer

05/06/2016

JCP Editors

Results from a study evaluating different tools intended to measure patient-reported health-related quality of life (HRQoL) in patients with breast cancer suggest that the Functional Assessment of Cancer...

...

05/06/2016

Journal of Clinical Pathways

Research in Review

Hormone Therapy More Cost-Effective Than Chemotherapy for Patients With HR+/HER2- Metastatic Breast Cancer

05/06/2016

JCP Editors

A study of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer has found that treatment with first-line chemotherapy offers no survival...

...

05/06/2016

Journal of Clinical Pathways